Richard W. Joseph, MD, internist and oncologist, Mayo Clinic, discusses molecular signatures in metastatic renal cell carcinoma (mRCC).
Richard W. Joseph, MD
Advertisement
Articles by Richard W. Joseph, MD
Richard W. Joseph, MD, internist and oncologist, Mayo Clinic, discusses the combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) in metastatic renal cell carcinoma (mRCC).
Richard W. Joseph, MD, internist and oncologist, Mayo Clinic, discusses considerations for frontline therapy selection in metastatic renal cell carcinoma (mRCC).
Richard W. Joseph, MD, internist and oncologist, Mayo Clinic, discusses the process of selecting frontline therapy in metastatic renal cell carcinoma (mRCC).
Advertisement
Latest Updated Articles
Dr. Joseph on Selecting Frontline Therapy in mRCCPublished: August 3rd 2019 | Updated:
Dr. Joseph on Factors Influencing Frontline Therapy Selection in mRCCPublished: August 5th 2019 | Updated:
Dr. Joseph on the Combination of Atezolizumab and Bevacizumab in mRCCPublished: August 23rd 2019 | Updated:
Dr. Joseph on Molecular Signatures in mRCCPublished: September 4th 2019 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
2
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
3
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
4
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
5